Cargando…

Intranasal delivery of mitochondria for treatment of Parkinson’s Disease model rats lesioned with 6-hydroxydopamine

The feasibility of delivering mitochondria intranasally so as to bypass the blood–brain barrier in treating Parkinson's disease (PD), was evaluated in unilaterally 6-OHDA-lesioned rats. Intranasal infusion of allogeneic mitochondria conjugated with Pep-1 (P-Mito) or unconjugated (Mito) was perf...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chang, Jui-Chih, Chao, Yi-Chun, Chang, Huei-Shin, Wu, Yu-Ling, Chang, Hui-Ju, Lin, Yong-Shiou, Cheng, Wen-Ling, Lin, Ta-Tsung, Liu, Chin-San
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8136477/ https://www.ncbi.nlm.nih.gov/pubmed/34011937 http://dx.doi.org/10.1038/s41598-021-90094-w

Ejemplares similares

Antitumor Actions of Intratumoral Delivery of Membrane-Fused Mitochondria in a Mouse Model of Triple-Negative Breast Cancers
por: Chang, Jui-Chih, et al.
Publicado: (2020)

IGF-1 as a Potential Therapy for Spinocerebellar Ataxia Type 3
por: Lin, Yong-Shiou, et al.
Publicado: (2022)

Mitochondrial transplantation regulates antitumour activity, chemoresistance and mitochondrial dynamics in breast cancer
por: Chang, Jui-Chih, et al.
Publicado: (2019)

Treadmill exercise alleviates short-term memory impairment in 6-hydroxydopamine-induced Parkinson’s rats
por: Cho, Han-Sam, et al.
Publicado: (2013)

Gelatin nanoparticle-mediated intranasal delivery of substance P protects against 6-hydroxydopamine-induced apoptosis: an in vitro and in vivo study
por: Lu, Cui-Tao, et al.
Publicado: (2015)

Lesioning of the Striatum Reverses Motor Asymmetry in the 6-Hydroxydopamine Rodent Model of Parkinsonism
por: Friehs, G. M., et al.
Publicado: (1991)

Changes in the Neuronal Architecture of the Hippocampus in a 6-Hydroxydopamine-Lesioned Rat Model of Parkinson Disease
por: Kim, Bohye, et al.
Publicado: (2022)

Peptide-mediated delivery of donor mitochondria improves mitochondrial function and cell viability in human cybrid cells with the MELAS A3243G mutation
por: Chang, Jui-Chih, et al.
Publicado: (2017)

Mitochondria DNA Change and Oxidative Damage in Clinically Stable Patients with Major Depressive Disorder
por: Chang, Cheng-Chen, et al.
Publicado: (2015)

Lipid profiles in the cerebrospinal fluid of rats with 6-hydroxydopamine-induced lesions as a model of Parkinson’s disease
por: Qiu, Jiewen, et al.
Publicado: (2023)

Epothilone B Benefits Nigral Dopaminergic Neurons by Attenuating Microglia Activation in the 6-Hydroxydopamine Lesion Mouse Model of Parkinson’s Disease
por: Yu, Zhongyuan, et al.
Publicado: (2018)

Gypenosides attenuate the development of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rat model of Parkinson’s disease
por: Shin, Keon Sung, et al.
Publicado: (2015)

Transcriptomic and Metabolic Network Analysis of Metabolic Reprogramming and IGF-1 Modulation in SCA3 Transgenic Mice
por: Lin, Yu-Te, et al.
Publicado: (2021)

Impaired Voluntary Wheel Running Behavior in the Unilateral 6-Hydroxydopamine Rat Model of Parkinson's Disease
por: Pan, Qi, et al.
Publicado: (2015)

Optogenetic Globus Pallidus Stimulation Improves Motor Deficits in 6-Hydroxydopamine-Lesioned Mouse Model of Parkinson’s Disease
por: Di Bisceglie Caballero, Sonia, et al.
Publicado: (2023)

Long-Term Motor Cortical Electrical Stimulation Ameliorates 6-Hydroxydopamine-Induced Motor Dysfunctions and Exerts Neuroprotective Effects in a Rat Model of Parkinson’s Disease
por: Kuo, Chi-Wei, et al.
Publicado: (2022)

Longitudinal assessment of motor function following the unilateral intrastriatal 6-hydroxydopamine lesion model in mice
por: Sun, Xiuping, et al.
Publicado: (2022)

Subtle Cardiovascular Dysfunction in the Unilateral 6-Hydroxydopamine-Lesioned Rat
por: Slack, K., et al.
Publicado: (2010)

Memory-enhancing activities of the aqueous extract of Albizia adianthifolia leaves in the 6-hydroxydopamine-lesion rodent model of Parkinson’s disease
por: Beppe, Galba Jean, et al.
Publicado: (2014)

Neuroprotective Effects of Herbal Ethanol Extracts from Gynostemma pentaphyllum in the 6-Hydroxydopamine-Lesioned Rat Model of Parkinson's Disease
por: Choi, Hyun Sook, et al.
Publicado: (2010)

Mitochondrial Dynamics and Mitophagy in the 6-Hydroxydopamine Preclinical Model of Parkinson's Disease
por: Galindo, Maria F., et al.
Publicado: (2012)

Parkinson’s Disease and the Heart: Studying Cardiac Metabolism in the 6-Hydroxydopamine Model
por: Silva da Fonsêca, Victor, et al.
Publicado: (2023)

Tumor Necrosis Factor-Associated Protein 1 (TRAP1) is Released from the Mitochondria Following 6-hydroxydopamine Treatment
por: Shin, Dong-Ik, et al.
Publicado: (2014)

Systemic oxidative stress and cognitive function in Parkinson’s disease with different PWMH or DWMH lesions
por: Chang, Ta-Chih, et al.
Publicado: (2021)

Transcriptome profiling of five brain regions in a 6‐hydroxydopamine rat model of Parkinson’s disease
por: Lyu, Ying, et al.
Publicado: (2021)

Electroacupuncture Produces the Sustained Motor Improvement in 6-Hydroxydopamine-Lesioned Mice
por: Yu, Yan, et al.
Publicado: (2016)

Regulatory Role of GSK-3β on NF-κB, Nitric Oxide, and TNF-α in Group A Streptococcal Infection
por: Chang, Yu-Tzu, et al.
Publicado: (2013)

Targeting the D1-N-methyl-d-aspartate receptor complex reduces l-dopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson’s rats
por: Song, Lu, et al.
Publicado: (2016)

Interactions of CaMKII with dopamine D2 receptors: roles in levodopa-induced dyskinesia in 6-hydroxydopamine lesioned Parkinson's rats
por: Zhang, SuFang, et al.
Publicado: (2014)

Effects of Subthalamic Nucleus Lesions and Stimulation upon Corticostriatal Afferents in the 6-Hydroxydopamine-Lesioned Rat
por: Walker, Ruth H., et al.
Publicado: (2012)

Upregulation of Cysteine Protease Cathepsin X in the 6-Hydroxydopamine Model of Parkinson’s Disease
por: Pišlar, Anja, et al.
Publicado: (2018)

Paeonol Protection Against Intrastriatal 6-Hydroxydopamine Rat Model of Parkinson’s Disease
por: Ghalami, Jamileh, et al.
Publicado: (2021)

Peiminine Reduces ARTS-Mediated Degradation of XIAP by Modulating the PINK1/Parkin Pathway to Ameliorate 6-Hydroxydopamine Toxicity and α-Synuclein Accumulation in Parkinson’s Disease Models In Vivo and In Vitro
por: Hsu, Yu-Ling, et al.
Publicado: (2021)

Electrophysiological and Neurochemical Considerations of Distinct Neuronal Populations in the Rat Pedunculopontine Nucleus and Their Responsiveness Following 6-Hydroxydopamine Lesions
por: Wang, Xuenan, et al.
Publicado: (2019)

Luteolin Modulates 6-Hydroxydopamine-Induced Transcriptional Changes of Stress Response Pathways in PC12 Cells
por: Hu, Ling-Wei, et al.
Publicado: (2014)

Chronic Spinal Cord Electrical Stimulation Protects Against 6-hydroxydopamine Lesions
por: Yadav, Amol P., et al.
Publicado: (2014)

Response of striosomal opioid signaling to dopamine depletion in 6-hydroxydopamine-lesioned rat model of Parkinson's disease: a potential compensatory role
por: Koizumi, Hidetaka, et al.
Publicado: (2013)

Application of the Physical Disector Principle for Quantification of Dopaminergic Neuronal Loss in a Rat 6-Hydroxydopamine Nigral Lesion Model of Parkinson's Disease
por: Fabricius, Katrine, et al.
Publicado: (2017)

The abnormal activation of D1R/Shp-2 complex involved in levodopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson’s rats
por: Wu, Na, et al.
Publicado: (2018)

Probiotic Enhancement of Antioxidant Capacity and Alterations of Gut Microbiota Composition in 6-Hydroxydopamin-Induced Parkinson’s Disease Rats
por: Tsao, Shu-Ping, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0437admnb3itcqq0v97naji00l